Disease · MONDO_0005150

age-related macular degeneration

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. age-related macular degeneration. Diseases, record MONDO_0005150. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005150

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: age-related macular degeneration; Open Targets
Open Targets ID: MONDO_0005150; Open Targets
Other names: AAMD - Age related macular degeneration, AGE RELAT MACULOPATHIES, AGE RELAT MACULOPATHY, AMD, AMD - Age-related macular degeneration, ARMD, ARMD - Age-related macular degeneration, Age Related Maculopathies, Age related macular degeneration (disorder) [Ambiguous], Age related maculopathy, Age-Related Macular Degenerations, Age-related macular degeneration (disorder), Amended, Degeneration, Age-Related Macular, Degeneration, Macular, Degenerations, Age-Related Macular, Degenerations, Macular, Dystrophies, Macular, Dystrophy, Macular, MACULAR DEGENERATION NOS, MACULOPATHIES AGE RELAT, MACULOPATHY AGE RELAT, Macular Degeneration, Macular Degenerations, Macular Degenerations, Age-Related, Macular Dystrophies, Macular Dystrophy, Macular degeneration (disorder), Macular degeneration (senile) of retina, unspecified, Maculopathies, Age Related, Maculopathy, Age Related, SMD - Senile macular degeneration, Senile macular degeneration, Senile macular degeneration of retina, Senile macular retinal degeneration, Unspecified senile macular degeneration, macular degeneration, age-related; Open Targets
Disease Ontology: DOID:10871; Disease Ontology
NCI Thesaurus: C84391; NCI Thesaurus
Orphanet: ORPHA:279; Orphanet
Highest stage of its drugs: Approval, for 1 of its 131 drugs, from TTD; Open Targets

Drugs131

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ECULIZUMAB	CHEMBL1201828	Antibody	Approval	TTD	2	1	1	Drugs and targets
RANIBIZUMAB	CHEMBL1201825	Antibody	Phase 3	ClinicalTrials.gov	118	118	114	Drugs and targets
AFLIBERCEPT	CHEMBL1742982	Protein	Phase 3	ClinicalTrials.gov	81	81	79	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 3	ClinicalTrials.gov	50	50	48	Drugs and targets
VERTEPORFIN	CHEMBL5314346	Small molecule	Phase 3	ClinicalTrials.gov	22	22	22	Drugs and targets
BROLUCIZUMAB	CHEMBL3707357	Antibody	Phase 3	ClinicalTrials.gov	18	18	18	Drugs and targets
PEGAPTANIB SODIUM	CHEMBL1201421	Small molecule	Phase 3	ClinicalTrials.gov	16	16	9	Drugs and targets
TRIAMCINOLONE ACETONIDE	CHEMBL1504	Small molecule	Phase 3	ClinicalTrials.gov	13	13	12	Drugs and targets
PEGPLERANIB SODIUM	CHEMBL3301576		Phase 3	ClinicalTrials.gov	12	12	7	Drugs and targets
ANECORTAVE ACETATE	CHEMBL2106613	Small molecule	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets

1 to 10 of 131

See all 131 drugs

Targets180

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	12	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
VEGFA	VEGF-A mRNA	11	VEGF-A mRNA RNAi inhibitor; Vascular endothelial growth factor A antagonist; Vascular endothelial growth factor A inhibitor	Phase 3	https://conductscience.org/library/genes/7422	Drugs and targets
FLT1	VEGFR1 mRNA	10	VEGFR1 mRNA rnai inhibitor; Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2321	Drugs and targets
KDR	Vascular endothelial growth factor receptor	10	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	10	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	8	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
PDGFRA	Platelet-derived growth factor receptor	7	Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5156	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	6	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
CSF1R	Macrophage colony-stimulating factor 1 receptor	5	Macrophage colony stimulating factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/1436	Drugs and targets
C5	Complement C5	4	Complement C5 binding agent; Complement C5 inhibitor; Complement C5 mRNA RNAi inhibitor	Approval	https://conductscience.org/library/genes/727	Drugs and targets

1 to 10 of 180

See all 180 targets

Trials384

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 11 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02307682	Efficacy and Safety of RTH258 Versus Aflibercept - Study 1	Phase 3	1,775	2019-10-31	Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization	AFLIBERCEPT, BROLUCIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00637377	Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)	Phase 3	1,240	2012-01-23	Macular Degeneration	AFLIBERCEPT, RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00509795	Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)	Phase 3	1,217	2012-04-16	Macular Degeneration	AFLIBERCEPT, RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00593450	Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial	Phase 3	1,208	2012-08-30	Age Related Macular Degeneration	BEVACIZUMAB, RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00891735	A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)	Phase 3	1,097	2013-01-18	Age-related Macular Degeneration	RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02434328	Efficacy and Safety of RTH258 Versus Aflibercept - Study 2	Phase 3	1,048	2019-10-31	Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization	AFLIBERCEPT, BROLUCIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT04777201	A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration	Phase 3	1,036	2025-10-24	Neovascular Age-related Macular Degeneration	FARICIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT04423718	Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye	Phase 3	1,011	2023-09-06	Neovascular Age-Related Macular Degeneration	AFLIBERCEPT	Open Targets' reading of its record	ClinicalTrials.gov
NCT04757636	OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)	Phase 3	998	2025-08-05	Neovascular Age-related Macular Degeneration	AFLIBERCEPT, SOZINIBERCEPT	Open Targets' reading of its record	ClinicalTrials.gov
NCT04757610	OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)	Phase 3	986	2025-07-22	Neovascular Age-related Macular Degeneration	RANIBIZUMAB, SOZINIBERCEPT	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 384

See all 384 trials

Comparisons in its trials74

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Brolucizumab 6mg vs Aflibercept 2mg: deaths from any cause	4 of 370	7 of 369	739	NCT02434328	Trial comparisons
Brolucizumab 6mg vs Aflibercept 2mg: serious adverse events	79 of 370	89 of 369	739	NCT02434328	Trial comparisons
SB11 (Proposed Ranibizumab Biosimilar) vs Lucentis (Ranibizumab): deaths from any cause	0 of 350	0 of 354	704	NCT03150589	Trial comparisons
SB11 (Proposed Ranibizumab Biosimilar) vs Lucentis (Ranibizumab): serious adverse events	52 of 350	52 of 354	704	NCT03150589	Trial comparisons
RBZ 0.5 mg: VA Only (Group I) vs RBZ 0.5 mg: VA and/or OCT (Group II): serious adverse events	30 of 334	45 of 336	670	NCT01780935	Trial comparisons
E10030 + Bevacizumab or Aflibercept vs Sham + Bevacizumab or Aflibercept: deaths from any cause	7 of 322	6 of 320	642	NCT01940887	Trial comparisons
E10030 + Bevacizumab or Aflibercept vs Sham + Bevacizumab or Aflibercept: serious adverse events	58 of 322	32 of 320	642	NCT01940887	Trial comparisons
E10030 + Ranibizumab vs Sham + Ranibizumab: deaths from any cause	4 of 312	4 of 314	626	NCT01940900	Trial comparisons
E10030 + Ranibizumab vs Sham + Ranibizumab: serious adverse events	56 of 312	49 of 314	626	NCT01940900	Trial comparisons
E10030 + Ranibizumab vs Sham + Ranibizumab: deaths from any cause	6 of 310	2 of 309	619	NCT01944839	Trial comparisons

1 to 10 of 74

See all 74 comparisons in its trials

Papers from its trials245

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40837068	RESULT	1	PubMed
40417242	RESULT	1	PubMed
39908134	RESULT	1	PubMed
38483382	RESULT	1	PubMed
37315571	RESULT	1	PubMed
33093900	RESULT	1	PubMed
31267688	RESULT	1	PubMed
30400586	RESULT	1	PubMed
29927057	RESULT	1	PubMed
28032115	RESULT	1	PubMed

1 to 10 of 245

See all 245 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005150

GET https://conductscience.org/api/diseases/v1/MONDO_0005150/drugs?page=2

API reference For AI assistants